C12N 2795/10371
Demonstrated in vivo effect
C12N2795/10371 (Demonstrated in vivo effect) appears on 19 US grants and 24 published applications in this corpus.
Search patents in C12N- Granted patents
- 19
- Published applications
- 24
- Assignees
- 9
- Inventors
- 27
- Latest grant
- 13 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 1 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 2 |
| 2020 | 3 | 3 |
| 2021 | 2 | 6 |
| 2022 | 6 | 5 |
| 2023 | 0 | 0 |
| 2024 | 3 | 2 |
| 2025 | 4 | 1 |
By publication year.
Recent patents
- Sequence specific antimicrobials13 May 2025US 12,295,993 B2The Rockefeller University
- Sequence specific antimicrobials29 Apr 2025US 12,285,466 B2The Rockefeller University
- Sequence specific antimicrobials29 Apr 2025US 12,285,467 B2The Rockfeller University
- Sequence specific antimicrobials11 Mar 2025US 12,246,061 B2The Rockefeller University
- Sequence specific antimicrobials17 Dec 2024US 12,168,040 B2The Rockefeller University
- Sequence specific antimicrobials7 Aug 2025US 2025/0249078 A1The Rockefeller University
- Bacterial delivery vehicle, process of production and uses thereof27 Jun 2024US 2024/0209326 A1
- Sequence specific antimicrobials23 May 2024US 2024/0165210 A1The Rockefeller University
- Crispr cas systems and lysogeny modules8 Dec 2022US 2022/0389392 A1Locus Biosciences, Inc.
- Sequence specific antimicrobials14 Jul 2022US 2022/0218795 A1The Rockefeller University
Most cited
By later US patents
- Sequence specific antimicrobials39US 10,660,943 B2The Rockefeller University · 2020
- Sequence specific antimicrobials10US 11,135,273 B2The Rockefeller University · 2021
- Sequence specific antimicrobials4US 11,452,765 B2The Rockefeller University · 2022
- Sequence specific antimicrobials3US 11,491,209 B2The Rockefeller University · 2022
- Sequence specific antimicrobials3US 11,491,210 B2The Rockefeller University · 2022